Self-renewing Pten -/-TP53 -/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Abou Kheir, Wassim ^a,b   Hynes, Paul G ^a   Martin, Philip ^a,c   Yin, Juan Juan ^a   Liu, Yen Nien ^a   Seng, Victoria ^a   Lake, Ross ^a   Spurrier, Joshua ^a   Kelly, Kathleen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, MOUSE; TUMOR MARKER;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER STEM CELL; CARCINOMA CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVITY; CELL CLONE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CELL POPULATION; CELL RENEWAL; CELLULAR PARAMETERS; CONTROLLED STUDY; DAUGHTER CELL; DISEASE ACTIVITY; GENE; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; PHENOTYPE; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROTOSPHERE; PTEN GENE; TP53 GENE; ADENOCARCINOMA; ANIMAL; BIOLOGICAL MODEL; BONE TUMOR; BRAIN TUMOR; CASTRATION; CELL PROLIFERATION; CELL SEPARATION; DRUG EFFECT; EPITHELIUM CELL; GENE INACTIVATION; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MULTICELLULAR SPHEROID; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANDROGENS; ANIMALS; BONE NEOPLASMS; BRAIN NEOPLASMS; CASTRATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL SEPARATION; EPITHELIAL CELLS; GENE KNOCKOUT TECHNIQUES; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MODELS, BIOLOGICAL; MULTIPOTENT STEM CELLS; NEOPLASM METASTASIS; OSTEOBLASTS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053943314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026112     Document Type: Article

References (29)

1. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, et al. (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34: 646-653.
2. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, et al. (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180: 1154-1160.
3. Clevers H, (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
5. Wang ZA, Shen MM, (2011) Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 30: 1261-1271.
6. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG, (2008) PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68: 1820-1825.
7. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, et al. (2009) Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69: 8555-8562.
8. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
9. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG, (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67: 6796-6805.
10. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI, (2011) Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2: 162.
11. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
12. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7: 403-417.
13. Visvader JE, (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23: 2563-2577.
14. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON, (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568-571.
15. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, et al. (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
16. Goldstein AS, Stoyanova T, Witte ON, (2010) Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 4: 385-396.
17. Harris WP, Mostaghel EA, Nelson PS, Montgomery B, (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85.
18. Mellado B, Codony J, Ribal MJ, Visa L, Gascon P, (2009) Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 11: 5-10.
19. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, et al. (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218: 505-513.
20. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
21. Agell L, Hernandez S, de Muga S, Lorente JA, Juanpere N, et al. (2008) KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 21: 1470-1478.
22. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, et al. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21: 1371-1378.
23. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
24. Martin PL, Liu YN, Pierce R, Abou-Kheir W, Casey O, et al. (2011) Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. American Journal of Pathology.
25. Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K, (2010) Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model. Stem Cells 28: 2129-2140.
26. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, et al. (2011) Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144: 187-199.
27. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
28. Sun H, Lesche R, Li DM, Liliental J, Zhang H, et al. (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 96: 6199-6204.
29. Logothetis CJ, Lin SH, (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28.